Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment.
OBJECTIVE
To evaluate possible prognostic factors regarding regression and relapse of complex atypical hyperplasia (CAH) and well-differentiated endometrioid adenocarcinoma (WDC) treated with conservative treatment.


METHODS
The retrospective study reviewed clinicopathologic, treatment, regression and relapse data from patients diagnosed with CAH or WDC who were treated with conservative treatment at 4 institutions. Potential factor evaluation was performed. SPSS 16 was used for statistical analyses.


RESULTS
Eighty-eight patients were included (51 had WDC, and 37 had CAH). Regression was evaluated in 88 patients, with a median follow-up of 61 (range 15-95) months. Seventy-seven (87.5%) patients regressed, and 11 (12.5%) had persistent or progressive disease. Univariate and multivariate analyses showed no factors associated with regression. Relapse was evaluated in 71 patients, with median follow-up of 54 (range 8-86) months. Twenty-five/71 (35.2%) patients experienced relapse. On univariate analysis, body mass index (BMI) 30 or higher (p=0.001), WCD at initial biopsy (p=0.017) and positive expression of post-treatment ki67 (p=0.033) were associated to a higher relapse probability. However, only BMI 30 or higher was significant on multivariate analysis (p=0.012). The Kaplan-Meier analysis revealed a higher relapse probability in the patients with BMI 30 or higher (p=0.001).


CONCLUSIONS
Obesity seems to be a risk factor for relapse of CAH or WDC with conservative treatment.
Department of Pathology, Dongguan Third People's Hospital, Dongguan, Guangdong Province, China.
Yu-Feng
YF
Yang
Department of Surgical Oncology, the Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Province, China.
Ying-Yang
YY
Liao
Department of Gynecology, Dongguan Third People's Hospital, Dongguan, Guangdong Province, China.
Xian-Lian
XL
Liu
Department of Pathology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangdong Province, China.
Shu-Guang
SG
Su
Department of Pathology, Gaoming District People's Hospital, Foshan, Guangdong Province, China.
Lin-Zhu
LZ
Li
Department of Surgical Oncology, the Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Province, China. Electronic address: pengnf2008@163.com.
Ning-Fu
NF
Peng
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D015992:Body Mass Index; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000473:pathology*; D018450:Disease Progression; D004714:Endometrial Hyperplasia / Q000188:drug therapy / Q000473:pathology*; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D018931:Antineoplastic Agents, Hormonal
Complex atypical hyperplasia; Conservative treatments; Endometrioid carcinoma; Regression; Relapse